Growth Inflection Point: With the post-COVID "normalization" complete, 2025 results mark a clear transition into a new growth cycle and a primary catalyst for stock appreciation. The Float Engine: SCI ...
Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...